Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. Issue 1 (2nd January 2020)

• Record Type: Journal Article
• Authors: Lanvers-Kaminsky, Claudia; Niemann, Andreas; Eveslage, Maria; Beck, Joachim; Köhnke, Thomas; Martin, Sonja; de Wit, Maike; Spriewald, Bernd; Hauspurg, Holger; Hoelzer, Dieter; Boos, Joachim; Gökbuget, Nicola
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 1(2020)
• Page Start: 138
• Page End: 145
• Publication Date: 2020-01-02
• Subjects: Adult ALL -- asparaginase activity -- drug monitoring -- pegylated E. coli asparaginase; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1658099
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The GMALL07/2003 protocol introduced pegylated E. coli asparaginase (PEG-ASNase) frontline for adults with acute lymphoblastic leukemia (ALL). PEG-ASNase (500 U/m 2, 1000 U/m 2, or 2000 U/m 2 ) was given once in induction and as part of three HD-MTX/PEG-ASNase cycles with two PEG-ASNase doses every other week in consolidation. PEG-ASNase activities were monitored in 1363 serum samples from 304 ALL patients. The overall rate of silent inactivation was low (5%) and did not differ between induction and consolidation. The successful targeting of PEG-ASNase activities ≥100 U/L depended on protocol and dose. Overall PEG-ASNase activities were higher during consolidation compared to induction. To target PEG-ASNase activities ≥100 U/L for 14 day with a single dose in induction, 2000 U/m 2 was more preferable than 1000 U/m 2 or 500 U/m 2 . During consolidation with two administrations every other week, 1000 U/m 2 and 2000 U/m 2 were similarly effective in sustaining PEG-ASNase ≥100 U/L activities over 14 days.